<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Dongkuk Pharma on Korea Invest Insights</title><link>https://koreainvestinsights.com/tags/dongkuk-pharma/</link><description>Recent content in Dongkuk Pharma on Korea Invest Insights</description><generator>Hugo -- gohugo.io</generator><language>en</language><copyright>koreainvestinsights.com · @korea_invest_insights</copyright><lastBuildDate>Thu, 29 Oct 2026 23:38:05 +0900</lastBuildDate><atom:link href="https://koreainvestinsights.com/tags/dongkuk-pharma/feed.xml" rel="self" type="application/rss+xml"/><item><title>Korea Quality Re-Rating Watch 2026-10-29: Daedeok, TFE, Dongkuk</title><link>https://koreainvestinsights.com/post/kr-daily-wrap-2026-10-29/</link><pubDate>Thu, 29 Oct 2026 16:30:00 +0900</pubDate><guid>https://koreainvestinsights.com/post/kr-daily-wrap-2026-10-29/</guid><description>&lt;h2 id="1-macro-dashboard"&gt;1. Macro Dashboard
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Indicator&lt;/th&gt;
 &lt;th&gt;Level&lt;/th&gt;
 &lt;th&gt;5-Day Change&lt;/th&gt;
 &lt;th&gt;Signal&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSPI&lt;/td&gt;
 &lt;td&gt;5,882&lt;/td&gt;
 &lt;td&gt;+7.0%&lt;/td&gt;
 &lt;td&gt;5-day rally, internals weak&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSDAQ&lt;/td&gt;
 &lt;td&gt;750.1&lt;/td&gt;
 &lt;td&gt;+0.2%&lt;/td&gt;
 &lt;td&gt;Flat&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;VIX&lt;/td&gt;
 &lt;td&gt;17.0&lt;/td&gt;
 &lt;td&gt;−12.7%&lt;/td&gt;
 &lt;td&gt;Calm&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;US 10Y&lt;/td&gt;
 &lt;td&gt;4.99%&lt;/td&gt;
 &lt;td&gt;+0.09pp&lt;/td&gt;
 &lt;td&gt;Stable&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;USD/KRW&lt;/td&gt;
 &lt;td&gt;1,338&lt;/td&gt;
 &lt;td&gt;+0.9%&lt;/td&gt;
 &lt;td&gt;Mild KRW softness&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Brent&lt;/td&gt;
 &lt;td&gt;$110.0&lt;/td&gt;
 &lt;td&gt;−5.0%&lt;/td&gt;
 &lt;td&gt;Declining&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;DXY&lt;/td&gt;
 &lt;td&gt;102.1&lt;/td&gt;
 &lt;td&gt;+0.2%&lt;/td&gt;
 &lt;td&gt;Flat&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;strong&gt;Regime: Korea = Bear / US = Bull.&lt;/strong&gt; KOSPI (200-DMA: 6,480) and KOSDAQ (200-DMA: 974) both sit well below their long-term averages. Market breadth at 20.6% of stocks above the 50-DMA — below the 25% Bear threshold — confirms the regime despite the headline index recovery. US indices (NASDAQ, S&amp;amp;P 500) remain above 200-DMA with VIX at 17 and HY OAS tightening to 3.18%; the Bull label holds. Korean rates are easing at the margin (KTB 3Y: 3.80%, KTB 10Y: 4.11%), but the spread story does not yet override the breadth signal.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="2-market-wrap"&gt;2. Market Wrap
&lt;/h2&gt;&lt;p&gt;&lt;em&gt;Source: KR Market Snapshot (2026-10-29). No same-day full close briefing was available; market character is derived from the DB snapshot.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Today&amp;rsquo;s session was broadly negative beneath the surface. Of 2,593 names tracked, 1,793 declined against 542 advances. The ADR proxy came in at 30.2 and the average stock return hit −1.59% — the kind of internal weakness that makes the KOSPI headline a poor guide to what actually happened.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Construction and energy led the selling.&lt;/strong&gt; 대우건설 (047040.KS) fell 18.57%, 한화솔루션 (009830.KS) −11.61%, LG에너지솔루션 (373220.KS) −8.60%, and SK이노베이션 (096770.KS) −7.09%. Crucially, foreign and institutional investors were aligned sellers in these names — a coordinated exit that differs from ordinary two-sided rotation.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Financials and data infrastructure attracted buyers.&lt;/strong&gt; KB금융 (105560.KS) +1.82% and 삼성화재해상보험 (000810.KS) +2.20% were foreign net-buy names. Domestically, institutions accumulated 삼성SDI (006400.KS), 삼성생명 (032830.KS), 신한지주 (055550.KS), and 현대모비스 (012330.KS). 한화비전 (489790.KS) surged 22.14% on institutional buying against foreign selling — the day&amp;rsquo;s strongest single-name momentum. 케이아이엔엑스 (093320.KQ) +13.28% was another institutional pick in the data infrastructure theme.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Passive flow context:&lt;/strong&gt; Program trading was a modest net +₩120bn; ETF net creation reached +₩1,151bn — a large inflow. But basis sits at −0.87, below the +1.0 threshold for passive-confirmed support. Large ETF inflows with negative basis suggest asset allocation rebalancing rather than directional conviction.&lt;/p&gt;
&lt;p&gt;The session&amp;rsquo;s character: selective risk-off, with institutional rotation out of construction, batteries, and renewables into financials and infrastructure. In a Bear regime where only one in five stocks is above its 50-DMA, quality and earnings momentum are the few filters that matter.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="3-todays-quality-re-rating-candidates"&gt;3. Today&amp;rsquo;s Quality Re-Rating Candidates
&lt;/h2&gt;&lt;p&gt;&lt;em&gt;Source: KR Meta Screener (2026-10-29), 88-ticker universe. The cross-screener overlap table shows no simple 2+ overlap pairs today; the meta screener ranks by independent evidence family count and family-capped scoring.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;The framework&amp;rsquo;s editorial lens: good businesses where institutional money is entering and the market is beginning to reprice the earnings story.&lt;/p&gt;
&lt;p&gt;Five names carry three or more independent evidence families. 티에프이 (425420.KQ) is the only name with all four layers — Quality Compounder + Smart Money Quality + Smart Money Earnings + Cycle Rerating — making it the highest-conviction setup in today&amp;rsquo;s screen.&lt;/p&gt;
&lt;h3 id="top-candidates"&gt;Top Candidates
&lt;/h3&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th style="text-align: right"&gt;Rank&lt;/th&gt;
 &lt;th&gt;Ticker&lt;/th&gt;
 &lt;th&gt;Name&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Meta Score&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Families&lt;/th&gt;
 &lt;th&gt;Screeners Hit&lt;/th&gt;
 &lt;th&gt;Key Metrics&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td&gt;353200.KQ&lt;/td&gt;
 &lt;td&gt;Daedeok Electronics (대덕전자)&lt;/td&gt;
 &lt;td style="text-align: right"&gt;57.2&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;Quality, Cycle Rerating, PEAD&lt;/td&gt;
 &lt;td&gt;ROE 5.3%, OP YoY +336%, Δmargin +3.4pp&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;072950.KQ&lt;/td&gt;
 &lt;td&gt;Bitsaem Electronics (빛샘전자)&lt;/td&gt;
 &lt;td style="text-align: right"&gt;54.6&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Quality, Cycle Rerating, PEAD&lt;/td&gt;
 &lt;td&gt;ROE 9.6%, OP YoY +77%, Δmargin +1.5pp&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;425420.KQ&lt;/td&gt;
 &lt;td&gt;TFE (티에프이)&lt;/td&gt;
 &lt;td style="text-align: right"&gt;54.5&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;Quality, Smart Money Quality, Smart Money Earnings, Cycle Rerating&lt;/td&gt;
 &lt;td&gt;ROE 16.6%, OP YoY +334%, Δmargin +11.1pp&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;086450.KQ&lt;/td&gt;
 &lt;td&gt;Dongkuk Pharma (동국제약)&lt;/td&gt;
 &lt;td style="text-align: right"&gt;54.4&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;Quality, Cycle Rerating, PEAD&lt;/td&gt;
 &lt;td&gt;ROE 9.9%, OP YoY +20%, Δmargin +0.5pp&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;080580.KQ&lt;/td&gt;
 &lt;td&gt;Okins Electronics (오킨스전자)&lt;/td&gt;
 &lt;td style="text-align: right"&gt;53.2&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Quality, Cycle Rerating, PEAD&lt;/td&gt;
 &lt;td&gt;ROE 15.4%, OP YoY +482%, Δmargin +8.9pp&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;6&lt;/td&gt;
 &lt;td&gt;252990.KQ&lt;/td&gt;
 &lt;td&gt;SEM C&amp;amp;S (샘씨엔에스)&lt;/td&gt;
 &lt;td style="text-align: right"&gt;52.2&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;Quality, Cycle Rerating, PEAD&lt;/td&gt;
 &lt;td&gt;ROE 9.7%, OP YoY +183%, Δmargin +9.1pp ⚠️&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;7&lt;/td&gt;
 &lt;td&gt;089890.KQ&lt;/td&gt;
 &lt;td&gt;Cosses (코세스)&lt;/td&gt;
 &lt;td style="text-align: right"&gt;37.9&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;Cycle Rerating, PEAD, Consensus Up&lt;/td&gt;
 &lt;td&gt;Δmargin +29.2pp, DART contract catalyst&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;8&lt;/td&gt;
 &lt;td&gt;021240.KS&lt;/td&gt;
 &lt;td&gt;Coway (코웨이)&lt;/td&gt;
 &lt;td style="text-align: right"&gt;37.4&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;Quality, RS80 Not-Late&lt;/td&gt;
 &lt;td&gt;ROE 17.1%, earnings preview filed Oct 29&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;9&lt;/td&gt;
 &lt;td&gt;003380.KS&lt;/td&gt;
 &lt;td&gt;Harim Holdings (하림지주)&lt;/td&gt;
 &lt;td style="text-align: right"&gt;35.5&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Cycle Rerating, RS80 Not-Late&lt;/td&gt;
 &lt;td&gt;Spin-off catalyst (DART Oct 26)&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;10&lt;/td&gt;
 &lt;td&gt;089860.KS&lt;/td&gt;
 &lt;td&gt;Lotte Rental (롯데렌탈)&lt;/td&gt;
 &lt;td style="text-align: right"&gt;34.5&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;Cycle Rerating, RS80 Not-Late&lt;/td&gt;
 &lt;td&gt;20D flow +11.2%, Focus Candidate&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;em&gt;⚠️ 샘씨엔에스: Net foreign+institutional selling −₩17.4bn absorbed by retail +₩8.4bn. Monitor whether institutional selling persists post the Oct 27 preliminary earnings disclosure.&lt;/em&gt;&lt;/p&gt;
&lt;hr&gt;
&lt;h3 id="deep-dives-top-3"&gt;Deep-Dives: Top 3
&lt;/h3&gt;&lt;p&gt;&lt;strong&gt;1. Daedeok Electronics (대덕전자, 353200.KQ) — Operating Leverage Meets Official Catalyst&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Daedeok is a PCB substrate manufacturer in Korea&amp;rsquo;s semiconductor packaging supply chain. Five independent evidence families at a meta score of 57.2 place it at the top of today&amp;rsquo;s queue. The operating leverage story is blunt: OP YoY +336%, margin expansion +3.4pp, with ROE rebuilding from a low base to 5.3%. The stock sits 27.6% below its 52-week high and 14.9% above the 50-DMA, leaving drift room intact. A DART IR event was filed Oct 23 — the catalyst layer is present. The caution is meaningful: net foreign+institutional selling of −₩6.3bn over five days signals sophisticated holders using strength to exit. The key question is whether the IR event reverses that flow or accelerates it.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;2. TFE (티에프이, 425420.KQ) — All Four Layers, Institutional Absorption&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;TFE makes semiconductor test handler equipment. This is the only name today with the full four-layer stack — Quality Compounder, Smart Money Quality, Smart Money Earnings, and Cycle Rerating — which is the most complete signal structure the framework can produce. The fundamentals confirm it: ROE 16.6%, OP YoY +334%, and margin expansion of +11.1pp indicate a business deep in an earnings inflection. The flow pattern is equally clear: foreign and qualified institutional investors bought a net +₩14.3bn over five days while retail sold −₩15.8bn. That&amp;rsquo;s institutional accumulation against retail distribution — one of the framework&amp;rsquo;s cleanest money-flow setups. A large-holding disclosure was filed at DART on Oct 23. Next check: whether the five-day +₩14.3bn buying pace continues or was a block repositioning.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;3. Dongkuk Pharmaceutical (동국제약, 086450.KQ) — Defensive Compounder in a Risk-Off Session&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Dongkuk Pharmaceutical is a domestic pharma and nutraceutical company with a long record of steady compounding. It scores on five evidence families including fundamental quality, cycle rerating, and post-earnings drift. OP YoY at +20% is the lowest of the top five — but on a healthcare platform with recurring revenues, consistent margin expansion (+0.5pp) and ROE of 9.9% make it a defensive quality candidate. Foreign and institutional investors absorbed retail selling of −₩6.2bn, suggesting quiet accumulation. A shareholder meeting has been called (DART Oct 12); if strategic restructuring is on the agenda, the catalyst layer strengthens. In a session where construction and batteries are being sold indiscriminately, healthcare compounders with earnings improvement are a logical destination for repositioning capital.&lt;/p&gt;
&lt;hr&gt;
&lt;p&gt;&lt;em&gt;Screener data as of 2026-10-29. Financial figures carry varying filing lags; most DART-sourced fundamentals are from Q4 2025 filings. These names are research candidates for further investigation, not investment recommendations.&lt;/em&gt;&lt;/p&gt;</description></item></channel></rss>